Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET
Company Participants
Andrew Faughnan - Senior Director, IR
Bradley Campbell - CEO, President & Director
Sebastien Martel - Chief Business Officer
Jeffrey Castelli - Chief Development Officer
Daphne Quimi - CFO
Conference Call Participants
Anupam Rama - JPMorgan Chase & Co.
Ritu Baral - Cowen and Company
Joseph Schwartz - SVB Securities
Dae Gon Ha - Stifel
Zhiqiang Shu - Berenberg
Ellie Merle - UBS
Operator
Good morning, ladies and gentlemen, and welcome to the Amicus Therapeutics Second Quarter 2022 Financial Results Conference Call and Webcast. [Operator Instructions]. As a reminder, this call is being recorded.
I would now like to turn the conference over to your host, Mr. Andrew Faughnan, Executive Director of Investor Relations. Please go ahead.
Andrew Faughnan
Thank you, Cole. Good morning. Thank you for joining our conference call to discuss Amicus Therapeutics second quarter 2022 financial results and corporate highlights. Leading today's call, we have Bradley Campbell, President and Chief Executive Officer; Daphne Quimi, Chief Financial Officer; Sebastien Martel, Chief Business Officer; and Dr. Jeff Castelli, Chief Development Officer. Joining for Q&A is Dr. Mitchell Goldman.
As referenced on Slide 2, we may make forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business as well as our plans and prospects. Our forward-looking statements should not be regarded as representation by us that any of our plans will be achieved. Any or all of the forward-looking statements made on this call may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. You are cautioned not to place undue reliance on any forward-looking statements, which speak only to the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update this presentation and conference call to reflect events or circumstances after the date hereof.
For a full discussion of such forward-looking statements and the risks and uncertainties that may impact them, we refer you to the forward-looking statements and Risk Factors section of our annual report on our Form 10-K and on our quarterly report Form 10-Q for the year ended June 30, 2022, to be filed later today with the Securities and Exchange Commission.
At this time, it is my pleasure to turn the call over to Bradley Campbell, President and Chief Executive Officer. Brad?